GlassScriptPhysician profile
Mandavi M Kulkarni
NPI 1770512659
$3,715.08
in general payments reported to CMS, 2019-2025
36 companies · $43.23 in 2025
The $43.23 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,013 · 2020: $979 · 2021: $335 · 2022: $21.92 · 2023: $223 · 2024: $100 · 2025: $43.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.61 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $520.33 | 2019-2021 | |
| Gilead Sciences, INC. | $413.83 | 2019-2021 | |
| Abbvie INC. | $402.10 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $289.43 | 2019-2025 | Zerbaxa |
| Janssen Biotech, INC. | $195.10 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $191.20 | 2019-2021 | |
| Astellas Pharma US INC | $151.67 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $151.48 | 2019-2020 | |
| Insmed, INC. | $140.89 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.54 | 2019-2020 | |
| Melinta Therapeutics, LLC | $101.37 | 2019-2020 | |
| Theratechnologies INC. | $99.82 | 2019-2021 | |
| Janssen Products, LP | $99.00 | 2019 | |
| Napo Pharmaceuticals INC | $90.46 | 2019-2020 | |
| Allergan, INC. | $78.11 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $56.24 | 2019-2021 | |
| Mylan Specialty L.P. | $51.63 | 2019-2020 | |
| Smith+Nephew, INC. | $49.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.13 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $44.82 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $38.10 | 2019 | |
| Ironwood Pharmaceuticals, INC | $36.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.23 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $31.85 | 2020 | |
| Convatec INC. | $28.52 | 2019 | |
| Shire North American Group INC | $27.24 | 2019 | |
| Bio Products Laboratory USA, INC. | $26.59 | 2019 | |
| Pfizer INC. | $26.22 | 2021 | |
| Aroa Biosurgery Incorporated | $24.14 | 2019 | |
| Janssen Scientific Affairs, LLC | $23.08 | 2019 | |
| Philips North America LLC | $22.47 | 2019 | |
| Novo Nordisk INC | $21.92 | 2022 | |
| Vifor Pharma, INC. | $18.93 | 2019 | |
| Csl Behring | $15.21 | 2019 | |
| Hospira, INC. | $15.09 | 2019 | |
| La Jolla Pharmaceutical Company | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandavi Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.